PRKDC and neoplasm: The immunosuppressive tumor microenvironment can compromise DNA-PKcs-targeted therapies; for instance, PD-L1 upregulation and impaired immune cell infiltration in triple-negative breast cancer models have been shown to diminish treatment efficacy, though combining DNA-PKcs inhibition with immunotherapy may overcome this limitation.